"Why oh why didn't he do that starting years ago??"
I suspect your question is somewhat rhetorical!
But to me, the answer is fairly obvious - Osiris conducted two well constructed placebo controlled, randomised clinical trials which showed no effect in adults. So unless the changes to manufacturing had produced a radical improvement in potency (and there is no good statistical evidence they had) then the chances of a small scale third RCT in adults succeeding were slim indeed. As you correctly point out, the whole clinical trial strategy was therefore built on a post hoc analysis of the earlier trial which showed a (statistically insignificant) positive trend in children - and the hope that the positive signal could be replicated in a small single arm study.
But as we know, hope is not a strategy, and MSB now faces the prospect of pitting a new small scale adult "study" against two well designed trials. Good luck with that, I say! Much better to focus limited resources on the other opportunities in the portfolio IMHO.
- Forums
- ASX - By Stock
- MSB
- CEO Itescu needs to go
CEO Itescu needs to go, page-764
-
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.09 |
Change
-0.015(1.36%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.08 | $1.10 | $1.08 | $823.4K | 763.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 20896 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.09 | 40903 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 39103 | 1.085 |
12 | 169527 | 1.080 |
16 | 146664 | 1.075 |
21 | 293571 | 1.070 |
9 | 583720 | 1.065 |
Price($) | Vol. | No. |
---|---|---|
1.090 | 39746 | 8 |
1.095 | 80610 | 10 |
1.100 | 57632 | 9 |
1.105 | 141946 | 13 |
1.110 | 68285 | 7 |
Last trade - 10.34am 19/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |